Solaris Endovascular today announced its formation to develop solutions for dialysis access and treating peripheral artery ...

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

More recently, drug-eluting stents (DESs) have emerged as the predominant ... Optimal Management of Multivessel Disease [FREEDOM] and Synergy Between PCI With TAXUS ® and Cardiac Surgery [SYNTAX ...

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

The CLEAR SYNERGY (OASIS 9) study, called "the largest trial ever ... More than 95% of patients were implanted with a drug-eluting stent. At month 3, C-reactive protein levels were significantly lower ...

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

The use of drug-eluting stents (DES) has become widespread as a result of their superior revascularization rates compared with those of bare-metal stents (BMS). 1 DES are increasingly being used ...

My first experience with Synergy was good. We needed very little help and the caregiver worked out perfectly. Unfortunately, she moved and we got a different worker who had no experience with ...

Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting ... everolimus-eluting stents. In addition, in Europe, it markets the SYNERGY Everolimus ...

The ELEGANCE registry, which is focused on historically underrepresented minorities and women, analyzed endovascular treatment ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a ...

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...